AstraZeneca drug combination on track to fight lung cancer

May 13 (Reuters) - A closely watched immune system-boosting drug cocktail from Britain's AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.